Sangamo Therapeutics' GAAP loss for 9M 2021 was $140.801 million, up 75% from $80.447 million in the previous year. Revenue declined 10.5% to $82.715 million from $92.392 million a year earlier.
Sangamo Therapeutics' GAAP loss for 9M 2021 was $140.801 million, up 75% from $80.447 million in the previous year. Revenue declined 10.5% to $82.715 million from $92.392 million a year earlier. 
investor.sangamo.com
English (US) 